These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16713103)

  • 1. Current status of angiogenesis inhibitors combined with radiation therapy.
    Nieder C; Wiedenmann N; Andratschke N; Molls M
    Cancer Treat Rev; 2006 Aug; 32(5):348-64. PubMed ID: 16713103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation therapy plus angiogenesis inhibition with bevacizumab: rationale and initial experience.
    Nieder C; Wiedenmann N; Andratschke NH; Astner ST; Molls M
    Rev Recent Clin Trials; 2007 Sep; 2(3):163-8. PubMed ID: 18474001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research progress on the mechanisms of combined bevacizumab and radiotherapy.
    Zhuang HQ; Yuan ZY; Wang P
    Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):129-34. PubMed ID: 24032532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
    Tandle A; Libutti SK
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis inhibition in solid tumors.
    Rosen LS
    Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of clinical trials of radiation combined with antiangiogenic therapy.
    Senan S; Smit EF
    Oncologist; 2007 Apr; 12(4):465-77. PubMed ID: 17470689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.
    Li Y; Liang XY; Yue YQ; Sheng L; Liu JK; Wang ZY; Chen G
    Tumour Biol; 2016 May; 37(5):6297-306. PubMed ID: 26619847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
    Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
    Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-angiogenic strategies in glioblastoma].
    Guillamo JS
    Rev Neurol (Paris); 2011 Oct; 167(10):662-7. PubMed ID: 21889779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
    Tabernero J
    Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
    Ferrara N; Hillan KJ; Novotny W
    Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.
    Wachsberger P; Burd R; Dicker AP
    Clin Cancer Res; 2003 Jun; 9(6):1957-71. PubMed ID: 12796357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis inhibitors in the treatment of lung cancer.
    Sun S; Schiller JH
    Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
    Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M
    Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy.
    Huber PE; Bischof M; Jenne J; Heiland S; Peschke P; Saffrich R; Gröne HJ; Debus J; Lipson KE; Abdollahi A
    Cancer Res; 2005 May; 65(9):3643-55. PubMed ID: 15867359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
    Cao C; Albert JM; Geng L; Ivy PS; Sandler A; Johnson DH; Lu B
    Cancer Res; 2006 Dec; 66(23):11409-15. PubMed ID: 17145887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis.
    Bachelier R; Confavreux CB; Peyruchaud O; Croset M; Goehrig D; van der Pluijm G; Clézardin P
    Int J Cancer; 2014 Sep; 135(6):1319-29. PubMed ID: 24615579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.